Tag Archives: PHA

Australian Studies Confirm Anisina as Potential Important New Weapon Against Melanoma

– Anisina kills melanoma cells regardless of their mutation status – Melanoma cells with normal and mutated BRAF gene killed by Anisina – Anisina to come into the clinic as…

DKSH Supports Growth for Vitabiotics in Hong Kong and Malaysia

DKSH, the leading Market Expansion Services provider with a focus on Asia, and Vitabiotics, Britain’s largest and fastest growing major vitamin supplement company, has signed an agreement to expand the…

Latin American Contract Research Organizations Set to Get More Local Outsourcing Opportunities

– Currently, multinational companies outsource a larger proportion of their clinical trials than local firms, finds Frost & Sullivan SAO PAULO, April 7, 2015 /PRNewswire/ — As market penetration stood at…

Global Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI(R) (crizotinib)

DARMSTADT, Germany and NEW YORK, April 7, 2015 /PRNewswire/ — Not intended for UK-based media  In the second and third quarters of 2015, Merck and Pfizer will begin co-promoting XALKORI…

SAFC Launches New EX-CELL® Advanced™ Products for Scalable, Efficient Biopharmaceutical Manufacturing

ST. LOUIS, April 7, 2015 /PRNewswire/ — Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that SAFC® Commercial (www.sigma-aldrich.com/safc), the Company’s business unit providing products and services for use in regulated pharmaceutical…

AMRI to Close Holywell, U.K. API Manufacturing Facility

ALBANY, N.Y., April 3, 2015 /PRNewswire/ — AMRI (NASDAQ: AMRI) announced today that it has decided to close its Holywell, U.K. facility following a consultation process with employee representatives. The Holywell…

Aptuit To Expand API Capacity Due To Increased Demand For Integrated Development

– Opens 1600L/1000L reactor stream at Oxford, UK and increases API capacity at Verona, Italy GREENWICH, Conn., April 3, 2015 /PRNewswire/ — Dr. Jonathan Goldman, CEO, Aptuit LLC, announced that…

Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company’s Development in Online and Offline MacroHealth Business

HONG KONG, April 1, 2015 /PRNewswire/ — Jintian Pharmaceutical Group Limited ("Jintian Pharmaceutical" or the "Company"; stock code: 2211) announced that Mr. Jin Dongtao, chairman and executive director purchased 40,000,000…